FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590290412> ?p ?o ?g. }

• W2590290412 abstract "Abstract The immunomodulatory drugs (also known as IMiDs) thalidomide, lenalidomide and pomalidomide, play a pivotal role in the treatment of multiple myeloma (MM). Recent studies have deciphered the mechanism of action of these drugs and shown that they directly interact with cereblon (CRBN), which is part of an E3-ubiquitin ligase complex. The IMiD-CRBN interaction selectively alters the affinity of CRBN to two important transcriptional factors, Ikaros (IKZF1) and Aiolos (IKZF3), leading to their ubiquitination and subsequent proteasomal degradation, representing a novel mechanism of therapy through ubiquitin-mediated alteration of gene expression. Several studies have underlined the importance of CRBN for the biologic activity of IMiDs, as both human cell lines and patient samples with acquired IMiD-resistance, exhibit a significant reduction of CRBN expression. However, it still remains unknown how CRBN expression is regulated, and subsequently, whether the acquired resistance to IMiDs is potentially druggable and reversible. In this study, we have used the IMiD-sensitive human myeloma cell lines OPM2 and NCI-H929, which were cultured with subtoxic doses of Lenalidomide and Pomalidomide for 4-6 months for acquisition of stable resistance. The lenalidomide- and pomalidomide-resistant cell lines (OPM2-LR, NCI-H929-LR and OPM2-PR, NCI-H929-PR subsequently) were then used as a model of acquired IMiD-resistance. In line with previous studies, we confirmed a significant reduction of CRBN expression, but not it downstream targets, IKZF1 and IKZF3, in the resistant cell lines, both at mRNA and protein level. Using methylation-specific melting curve analysis, we next showed that the downregulation of CRBN is not due to promoter DNA methylation. We therefore proceeded with the assessment of chromatin accessibility through nucleosome positioning using AcceSsIble. Our data show that acquired IMiD-resistance is accompanied by increased nucleosome occupancy (and thus decreased chromatin accessibility - figure 1A) rather than DNA methylation, an event that is also more prominent in promoters and enhancers (figure 1B). Among the top 100 genes whose promoters are nucleosome-occupied was CRBN, an event that could explain the reduced expression observed upon acquired IMiD-resistance. Since both DNA methylation and nucleosome positioning are two potentially reversible epigenetic modifications, we next treated the resistant cell lines with a combination of decitabine (a DNA-methyl-transferase inhibitor) and GSK-126 (an EZH2-inhibitor) for 3 days and then exposed them again to IMiDs. Even though the combination treatment by itself was mildly toxic for the cells, cell viability was even more reduced upon treatment with IMiDs three days after exposure to this combination of epidrugs, suggesting that epigenetic reprogramming and resensitization of IMiD-resistant cells could be feasible (figure 1C). Taken together, our data could potentially explain the mechanism behind CRBN downregulation observed upon IMiD-resistance and provide evidence for possible epigenetic resensitising myeloma cells to IMiDs. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare." @default.
• W2590290412 created "2017-03-03" @default.
• W2590290412 creator A5003689547 @default.
• W2590290412 creator A5008115982 @default.
• W2590290412 creator A5008481807 @default.
• W2590290412 creator A5031678980 @default.
• W2590290412 creator A5059259645 @default.
• W2590290412 creator A5076293102 @default.
• W2590290412 date "2016-12-02" @default.
• W2590290412 modified "2023-09-27" @default.
• W2590290412 title "Cereblon Is Downregulated By Promoter Nucleosome Occupancy in Acquired IMiD Resistance: The Potential of IMiD Resensitization By Epigenetic Therapy" @default.
• W2590290412 doi "https://doi.org/10.1182/blood.v128.22.3258.3258" @default.
• W2590290412 hasPublicationYear "2016" @default.
• W2590290412 type Work @default.
• W2590290412 sameAs 2590290412 @default.
• W2590290412 citedByCount "0" @default.
• W2590290412 crossrefType "journal-article" @default.
• W2590290412 hasAuthorship W2590290412A5003689547 @default.
• W2590290412 hasAuthorship W2590290412A5008115982 @default.
• W2590290412 hasAuthorship W2590290412A5008481807 @default.
• W2590290412 hasAuthorship W2590290412A5031678980 @default.
• W2590290412 hasAuthorship W2590290412A5059259645 @default.
• W2590290412 hasAuthorship W2590290412A5076293102 @default.
• W2590290412 hasConcept C104317684 @default.
• W2590290412 hasConcept C134459356 @default.
• W2590290412 hasConcept C203014093 @default.
• W2590290412 hasConcept C25602115 @default.
• W2590290412 hasConcept C2776063141 @default.
• W2590290412 hasConcept C2776364478 @default.
• W2590290412 hasConcept C2778524551 @default.
• W2590290412 hasConcept C2778540781 @default.
• W2590290412 hasConcept C2779609412 @default.
• W2590290412 hasConcept C502942594 @default.
• W2590290412 hasConcept C54355233 @default.
• W2590290412 hasConcept C81885089 @default.
• W2590290412 hasConcept C86803240 @default.
• W2590290412 hasConceptScore W2590290412C104317684 @default.
• W2590290412 hasConceptScore W2590290412C134459356 @default.
• W2590290412 hasConceptScore W2590290412C203014093 @default.
• W2590290412 hasConceptScore W2590290412C25602115 @default.
• W2590290412 hasConceptScore W2590290412C2776063141 @default.
• W2590290412 hasConceptScore W2590290412C2776364478 @default.
• W2590290412 hasConceptScore W2590290412C2778524551 @default.
• W2590290412 hasConceptScore W2590290412C2778540781 @default.
• W2590290412 hasConceptScore W2590290412C2779609412 @default.
• W2590290412 hasConceptScore W2590290412C502942594 @default.
• W2590290412 hasConceptScore W2590290412C54355233 @default.
• W2590290412 hasConceptScore W2590290412C81885089 @default.
• W2590290412 hasConceptScore W2590290412C86803240 @default.
• W2590290412 hasLocation W25902904121 @default.
• W2590290412 hasOpenAccess W2590290412 @default.
• W2590290412 hasPrimaryLocation W25902904121 @default.
• W2590290412 hasRelatedWork W1977551542 @default.
• W2590290412 hasRelatedWork W1992168390 @default.
• W2590290412 hasRelatedWork W1995630361 @default.
• W2590290412 hasRelatedWork W1998365877 @default.
• W2590290412 hasRelatedWork W1998897876 @default.
• W2590290412 hasRelatedWork W2048499425 @default.
• W2590290412 hasRelatedWork W2184234315 @default.
• W2590290412 hasRelatedWork W2197645556 @default.
• W2590290412 hasRelatedWork W2344214681 @default.
• W2590290412 hasRelatedWork W2483032490 @default.
• W2590290412 hasRelatedWork W2502380292 @default.
• W2590290412 hasRelatedWork W2508746241 @default.
• W2590290412 hasRelatedWork W2554184027 @default.
• W2590290412 hasRelatedWork W2555000944 @default.
• W2590290412 hasRelatedWork W2562415176 @default.
• W2590290412 hasRelatedWork W2572334990 @default.
• W2590290412 hasRelatedWork W2943837693 @default.
• W2590290412 hasRelatedWork W2950986812 @default.
• W2590290412 hasRelatedWork W2979768092 @default.
• W2590290412 hasRelatedWork W99095751 @default.
• W2590290412 isParatext "false" @default.
• W2590290412 isRetracted "false" @default.
• W2590290412 magId "2590290412" @default.
• W2590290412 workType "article" @default.